Physician/scientist from the Dana-Farber Cancer Institute and Harvard Medical School Boston, USA. Shom has spurred the development of clinical trials focussing on CDK4/6 inhibitors for HER 2 breast cancers.
Dr Goel is a physician-scientist at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He graduated from the University of Adelaide Medical School in 2002 and subsequently completed medical oncology training in Sydney. In 2009, he relocated to Boston to conduct his doctoral research in the laboratory of Rakesh K. Jain at the Massachusetts General Hospital. He was appointed as a Goldfarb-Rudkin Fellow in Breast Oncology at Dana-Farber in 2009, and has since developed a strong interest in new therapies targeting fundamental oncogenes in breast cancers. Of note, he has created a novel transgenic mouse model of HER2-positive disease that has facilitated the discovery of key mechanisms underlying resistance to HER2-blockade. His landmark discoveries in the laboratory have spurred the development of new clinical trials for patients with metastatic HER2-positive breast cancer. More recently, he has focused on the interactions between oncogenic signaling pathways and the immune microenvironment in breast cancers. Dr Goel currently sits on a number of international advisory panels, leads several clinical trials, and oversees the translational studies for two global randomized studies of CDK4/6 inhibitors in breast cancer. He is the recipient of two University Medals, the Bryan Hudson Medal (RACP), a Fulbright Scholarship, an ASCO Young Investigator Award, and a Fellowship from the American Australian Association.